Sponsor pipeline

Roche / Genentech clinical trial pipeline

Get alerts when Roche / Genentech's trials change

250 active trials 104 recruiting 90 Phase 3 48 disease areas 134 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 46 of 134 changes on 19 trials

2026-08-22
Trial terminated
Trial terminated: The trial was terminated due to sponsor decision.
Enrollment reduced: 136 → 3 participants
Primary completion moved earlier: 2030-06-01 → 2026-06-24
Completion moved earlier: 2030-06-01 → 2026-06-24
NCT07214662 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a… · Phase 1
2026-08-11
Trial status changed: Completed → Terminated
Trial terminated: The study was terminated prematurely by the Sponsor due to observation of dose-limiting adverse events meeting the prot...
NCT06961370 A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics… · Phase 1
2026-09-04
Primary completion pushed: 2026-10-31 → 2027-06-30
Trial sites reduced: 164 → 161 locations
Completion pushed: 2026-10-31 → 2027-06-30
NCT03178552 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments… · Phase 2/3
2026-09-05
Primary completion pushed: 2026-09-30 → 2027-12-31
Completion pushed: 2026-09-30 → 2027-12-31
NCT06274515 A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies · Phase 4
2026-08-29
Primary completion pushed: 2026-10-31 → 2027-06-30
Completion pushed: 2026-11-28 → 2027-06-30
NCT00781612 A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With… · Phase 2
2026-08-26
Primary completion pushed: 2026-06-30 → 2026-10-14
Completion pushed: 2026-06-30 → 2026-10-14
NCT04770896 A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone… · Phase 3
2026-08-15
Primary completion pushed: 2026-03-10 → 2026-08-25
NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration · Phase 1/2
2026-08-13
Primary endpoint(s) modified
Trial completed
NCT06106828 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… · Phase 3
2026-08-14
Primary endpoint(s) modified
Trial arms changed: 3 → 4
NCT05704361 A Study to Investigate the Safety, Tolerability, and Processing by the Body of… · Phase 1
2026-08-28
Enrollment reduced: 720 → 378 participants
Primary completion moved earlier: 2029-09-30 → 2026-10-31
Completion moved earlier: 2030-04-30 → 2026-11-28
NCT00781612 A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With… · Phase 2
2026-08-07
Enrollment reduced: 450 → 165 participants
Enrollment closed, study ongoing
Trial sites reduced: 41 → 36 locations
NCT05581004 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single… · Phase 1
2026-08-14
Enrollment reduced: 1200 → 901 participants
Trial completed
Primary completion moved earlier: 2026-11-06 → 2026-03-18
Completion moved earlier: 2026-11-06 → 2026-03-18
NCT05872763 A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be…
2026-09-04
Phase changed: Phase 2 → Phase 3
NCT07503340 A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and… · Phase 3
2026-08-20
Phase changed: Phase 1/2 → Phase 3
Trial completed
NCT06624059 A Study to See How Well and How Safely Different Treatments Work in a Group of… · Phase 3
2026-09-04
Enrollment closed, study ongoing
NCT04524871 A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment… · Phase 1/2
2026-09-02
Enrollment reopened
Trial sites expanded: 145 → 210 locations
NCT05646862 A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With… · Phase 3
2026-09-02
Enrollment closed, study ongoing
Completion moved earlier: 2029-08-30 → 2029-07-31
NCT05562947 A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System… · Phase 3
2026-09-02
Trial completed
NCT03157635 Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in… · Phase 1/2
2026-09-03
Enrollment closed, study ongoing
Final enrollment: 3 participants — 8% of the 40 planned
NCT07246941 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of… · Phase 1
2026-09-03
Enrollment closed, study ongoing
Final enrollment: 6 participants (planned 50)
Primary completion moved earlier: 2029-12-03 → 2027-03-23
Completion moved earlier: 2030-05-30 → 2027-03-23
NCT07234942 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics… · Phase 1

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-09-01 NCT07797478 A Study of RO7890597 in Healthy Adult Volunteers Phase 1 Recruiting
2026-08-24 NCT07781644 Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease Phase 1/2 Not Yet Recruiting
2026-08-24 NCT07781657 Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease Phase 2 Not Yet Recruiting
2026-08-06 NCT07749157 A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple… Phase 1 Not Yet Recruiting

Active trials by phase

Phase 1
53
Phase 1/2
26
Phase 2
52
Phase 2/3
4
Phase 3
86
Phase 4
10
Not charted: 19 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 250

NCT IDTitleConditionStatusUpdated
Phase 4
NCT06274515 A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies Breast Cancer Recruiting 2026-09-04
NCT05861986 A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early… Muscular Atrophy, Spinal Recruiting 2026-09-03
NCT04853251 A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related… Neovascular Age-related Macular Degeneration Recruiting 2026-09-02
NCT07609719 A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple… Multiple Sclerosis Recruiting 2026-08-13
NCT05861999 A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric… Muscular Atrophy, Spinal Recruiting 2026-08-11
NCT05224102 A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented… Diabetic Macular Edema Active, Not Recruiting 2026-08-25
NCT06795048 A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants… Neovascular Age-related Macular Degeneration (nAMD) Active, Not Recruiting 2026-07-31
NCT05181618 A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants… Severe Hemophilia A Active, Not Recruiting 2026-07-27
NCT05232929 Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA) Spinal Muscular Atrophy Active, Not Recruiting 2026-07-16
NCT07483450 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… Relapsing Multiple Sclerosis Active, Not Recruiting 2026-07-06
Phase 3
NCT07416604 A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in… Hemophilia A Recruiting 2026-09-04
NCT06065748 A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a… Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Recruiting 2026-09-03
NCT06084936 A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in… Lymphoma Recruiting 2026-09-03
NCT06790693 A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and… Breast Cancer Recruiting 2026-09-03
NCT07174310 A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in… Parkinson's Disease Recruiting 2026-09-03
NCT05862285 A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La… Cancer Recruiting 2026-09-02
NCT05646862 A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With… Breast Cancer Recruiting 2026-09-01
NCT07541079 A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant… Early Breast Cancer Recruiting 2026-09-01
NCT03683251 Extension Study for the Port Delivery System With Ranibizumab (Portal) Neovascular Age-Related Macular Degeneration Recruiting 2026-08-31
NCT06819891 A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart… Moderately to Severely Active Crohns Disease Recruiting 2026-08-31
NCT05894239 A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo… Metastatic Breast Cancer Recruiting 2026-08-25
NCT06847542 A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD Neovascular Age-related Macular Degeneration Recruiting 2026-08-21
NCT07177352 Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's… Alzheimers Disease Recruiting 2026-08-21
NCT06819878 A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With… Moderately to Severely Active Crohns Disease Recruiting 2026-08-20
NCT07158242 A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121)… Moderately to Severely Active Ulcerative Colitis Recruiting 2026-08-14
See all 250 active Roche / Genentech trials with filters →

Disease areas by active trials, top 10 of 48

Breast Cancer (28) · Multiple Sclerosis (23) · Non-Small Cell Lung Cancer (NSCLC) (18) · Lung Cancer (17) · Non-Hodgkin Lymphoma (9) · Alzheimer's Disease (8) · Liver Cancer (8) · Multiple Myeloma (8) · Obesity (8) · Colorectal Cancer (6)

Get alerts when Roche / Genentech's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free